Naltrexone FDA Link Generic

Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Also Known As:

ReVia; Antaxone; Celupan; EN-1639A; Nalorex; Naltrexone Hydrochloride; Nemexin; Trexan; EN 1639A; EN1639A; Morphinan-6-one, 17- (cyclopropylmethyl)- 4,5- epoxy- 3,14- dihydroxy- , (5alpha)-

Pharmalogical Action Categories:

Narcotic Antagonists

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Opiate Alkaloids: 5944
    - Morphinans: 33
      - Naloxone: 5958
        Naltrexone: 2720
- Bridged-Ring Heterocyclic Compounds
  - Morphinans: 33
    - Naloxone: 5958
      - Naltrexone: 2720
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - Morphinans: 33
      - Naloxone: 5958
        Naltrexone: 2720
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Phenanthrenes: 27
    - Morphinans: 33
      - Naloxone: 5958
        Naltrexone: 2720

17- (cyclopropylmethyl)- 4,5- epoxy- 3,4- dihydroxy- 6- ((phthalaldehydecarboxamido)acetamido)morphinan

Bio-Agent Context: Research Results